Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Groove Botanicals, Inc. (GRVE)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
310 Fourth Avenue South 55415
Minneapolis, MN, US
Minneapolis, MN, US
CEO
Kent A. Rodriguez
Website
groovebotanicals.com
IPO
2012-09-25
CIK 918573 ISIN US3988451072
Description
Groove Botanicals, Inc. is an enterprise primarily focused on innovating electric vehicle (EV) battery technologies. Established in 1991, the company previously operated under the name Avalon Oil & Gas, Inc., officially adopting its current designation in May 2018. Its corporate headquarters are located in Minneapolis, Minnesota.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.7K
Beta
-0.16
Float Shares
59.64M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +24.00% | -10.58% | -41.88% | +9.41% | +86.00% | -90.76% | -85.91% | -53.50% | -81.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Levered)
0.00
-99.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-8,198.02
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+40.0% ★ Q1'26: -7.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +9.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.3% Q1'26: +1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-93.7K
OE per share TTM
0.00
Owner's Yield
-16.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,191.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PRESIDENT, SOLE DIRECTOR AND SOLE STOCKHOLDER. | 26.18M | 11.00% | — | — | — | — | IN | UNITED STATES | 2006-09-01 | ↗ |
| 2 | Lorraine DiPaolo | 6.68M | 6.71% | 6.68M | — | 6.68M | — | IN | New York | 2010-08-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008-06-30 | UTEK CORP | 10% Owner | S-Sale | D | Common Stock | 132,500 | 0.11 | 14.6K | 3,373,107 | — | ↗ |
| 2008-04-04 | UTEK CORP | 10% Owner | S-Sale | D | Common Stock | 25,000 | 0.21 | 5.3K | 3,505,607 | — | ↗ |
| 2008-03-28 | UTEK CORP | 10% Owner | S-Sale | D | Common Stock | 9,700 | 0.10 | 970.00 | 3,530,607 | — | ↗ |
| 2008-03-26 | UTEK CORP | 10% Owner | S-Sale | D | Common Stock | 50,000 | 0.10 | 5.0K | 3,540,307 | — | ↗ |
| 2008-03-25 | UTEK CORP | 10% Owner | S-Sale | D | Common Stock | 30,000 | 0.10 | 3.0K | 3,590,307 | — | ↗ |
| 2007-08-21 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 7,472 | 0.65 | 4.9K | 1,000 | — | ↗ |
| 2007-08-21 | Barton Douglas W | Director | S-Sale | D | Common Stock | 10,000 | 0.62 | 6.2K | 57,547 | — | ↗ |
| 2007-08-14 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 5,000 | 0.65 | 3.3K | 15,972 | — | ↗ |
| 2007-08-13 | Barton Douglas W | Director | S-Sale | D | Common Stock | 20,500 | 0.58 | 11.9K | 67,547 | — | ↗ |
| 2007-08-10 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 5,000 | 0.60 | 3.0K | 20,972 | — | ↗ |
| 2007-08-10 | Barton Douglas W | Director | S-Sale | D | Common Stock | 14,500 | 0.60 | 8.7K | 88,047 | — | ↗ |
| 2007-08-09 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,000 | 0.61 | 1.2K | 25,972 | — | ↗ |
| 2007-08-08 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 4,000 | 0.57 | 2.3K | 29,972 | — | ↗ |
| 2007-08-07 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,000 | 0.62 | 1.2K | 33,972 | — | ↗ |
| 2007-07-31 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 1,000 | 0.65 | 651.00 | 35,972 | — | ↗ |
| 2007-07-27 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,500 | 0.63 | 1.6K | 43,472 | — | ↗ |
| 2007-07-25 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 5,000 | 0.70 | 3.5K | 51,972 | — | ↗ |
| 2007-07-23 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,000 | 0.60 | 1.2K | 60,972 | — | ↗ |
| 2007-07-20 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 1,000 | 0.55 | 550.00 | 0 | — | ↗ |
| 2007-07-18 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 3,000 | 0.55 | 1.7K | 72,972 | — | ↗ |
| 2007-07-17 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 3,000 | 0.61 | 1.8K | 75,972 | — | ↗ |
| 2007-07-13 | Barton Douglas W | Director | S-Sale | D | Common Stock | 5,000 | 0.84 | 4.2K | 102,547 | — | ↗ |
| 2007-07-12 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,000 | 0.80 | 1.6K | 78,972 | — | ↗ |
| 2007-07-11 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,000 | 0.78 | 1.6K | 80,972 | — | ↗ |
| 2007-07-10 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 5,000 | 0.82 | 4.1K | 82,972 | — | ↗ |
| 2007-07-09 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 3,000 | 0.80 | 2.4K | 92,972 | — | ↗ |
| 2007-07-06 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 1,000 | 0.80 | 800.00 | 95,972 | — | ↗ |
| 2007-07-05 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,500 | 0.75 | 1.9K | 100,047 | — | ↗ |
| 2007-07-03 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,500 | 0.57 | 1.4K | 102,547 | — | ↗ |
| 2007-06-11 | KAPLAN THAD | Director | S-Sale | D | Common Stock | 2,500 | 0.50 | 1.3K | 105,047 | — | ↗ |
| 2007-05-17 | KAPLAN THAD | Director | C-Conversion | A | Common Stock | 107,547 | 0.00 | — | 107,547 | — | ↗ |
| 2007-05-17 | Barton Douglas W | Director | X-InTheMoney | D | Warrant | 40,556 | 0.20 | 8.1K | 0 | — | ↗ |
| 2007-03-28 | UTEK CORP | 10% Owner | A-Award | D | Common Stock | 36,710,526 | 0.02 | 859.0K | 71,841,668 | — | ↗ |
| 2006-11-08 | UTEK CORP | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 35,131,142 | — | ↗ |
| 2006-05-17 | KAPLAN THAD | Director | X-InTheMoney | D | Warrant | 40,556 | 0.20 | 8.1K | 0 | — | ↗ |
| 2006-05-01 | Barton Douglas W | Director | A-Award | A | Warrant | 1,000,000 | 0.03 | 25.0K | 0 | — | ↗ |
| 2006-03-31 | RODRIGUEZ KENT A | Director / Officer / 10% Owner | — | D | Series A Preferred Stock | 0 | 0.00 | — | 100 | — | ↗ |
| 2006-03-31 | KAPLAN THAD | Director | A-Award | A | Warrant | 1,000,000 | 0.01 | 10.0K | 2,000,000 | — | ↗ |
| 2006-03-31 | Barton Douglas W | Director | — | D | Warrant | 1,000,000 | 0.01 | 10.0K | 0 | — | ↗ |
| 2006-01-04 | RODRIGUEZ KENT A | Director / Officer / 10% Owner | A-Award | A | Warrant | 1,000,000 | 0.01 | 10.0K | 1,000,000 | — | ↗ |
| 2005-12-20 | RODRIGUEZ KENT A | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 17,350,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
59.64M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kent A. Rodriguez | Chairman, Chief Executive Officer, President, Chief Financial Officer, Treasurer & Secretary | 121.2K | male |
| Menno Wiebe | Advisor | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GRVE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
